Key result
Multimodal treatments improve Ewing sarcoma prognosis by ~70% despite persistent relapse risk.
Why the study?
Despite decades of research, clinical improvement in Ewing sarcoma has not been achieved through novel targeted therapies, and relapse rates remain unacceptably high.
Population
Children and adolescents with Ewing sarcoma
Design
Review article
Authors
Loading...
Supports multimodal therapy as Ewing sarcoma standard; leaves open targeted agents to address persistent relapse.
Despite improvements in survival with multimodal therapy, the high relapse rate in Ewing sarcoma highlights the urgent need for novel targeted treatments.
Dirksen et al. (2010) conducted a review in Ewing sarcoma. Multimodal treatments (chemotherapy and local treatment) was evaluated. Multimodal treatments including chemotherapy and local treatment have improved Ewing sarcoma prognosis by up to 70%, although a 30% relapse rate remains.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: